Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

SAN FRANCISCO -- Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.

Scientists have found the first compelling evidence that cognitive training can boost levels of a brain chemical that ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

Growth fueled by the increasing incidence of Alzheimer's disease, growing aging population, and continued development in ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia gravis, but long-term results will be key.

The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress ...

Data Safety Monitoring Committee (DSMC): The company announced completion of the fourth and final scheduled safety review by the DSMC for the ORCA-OL trial. Adverse events were mostly mild in severity ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and Ultomiris (ravulizumab) – which are dosed by intravenous infusion every two and ...

A new McGill-led study reveals that digital brain exercises can rejuvenate aging brain systems responsible for learning and ...

When a drug gets FDA approval, it means it’s been rigorously ... Like Botox, Xeomin is made from botulinum toxin type A, a ...

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...